{"id":1643,"date":"2020-03-17T18:10:55","date_gmt":"2020-03-17T10:10:55","guid":{"rendered":"http:\/\/www.bioactivescreeninglibrary.com\/?p=1643"},"modified":"2022-01-07T10:56:45","modified_gmt":"2022-01-07T02:56:45","slug":"modeled-aspirin-covering-critical-period-recurrence-easy-administer","status":"publish","type":"post","link":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2020\/03\/17\/modeled-aspirin-covering-critical-period-recurrence-easy-administer\/","title":{"rendered":"We modeled aspirin to covering the critical period where recurrence easy to administer"},"content":{"rendered":"

Good riskbenefit profile relative to chemotherapy, we hypothesize that Enzalutamide CYP17 inhibitor<\/a> aspirin might represent a cost-effective strategy for the adjuvant treatment of Stage I and II CRC where the risk of cancer recurrence is low. Such patients are currently not routinely offered adjuvant chemotherapy and are followed-up with observation alone. As the number needed to treat to prevent one CRC recurrence or death will be much larger for Stage I and II CRC than for Stage III disease, global cost-effectiveness will be an important consideration for advocating treatment in low relapserisk cancers. To date, although there have been several cost-effectiveness analyses of aspirin in the primary prevention of CRC, no studies have been undertaken to evaluate the cost-effectiveness of aspirin in the adjuvant or secondary cancer prevention setting. Given the ever escalating costs of cancer care and constraints in health resources globally, a cost-effectiveness analysis of adjuvant aspirin in the context of treatment of cancer, in particular low-risk cancer, is both timely and important. The primary objective of this study is to determine the cost-effectiveness of aspirin as adjuvant therapy for Stages I and II CRC in the United States population. The U.S. was chosen as the population under study due to the relative availability of data for model input. The study model focused solely on sporadic CRC as it is the most common and relevant type of CRC. The model assumed a uniform treatment benefit effect and fatality risk across the various regions of the ascending, transverse, descending and sigmoid colon and rectum, and all treatment effects were assumed to be immediate. Disease-free survival ratios and cancer-specific survival ratios for capecitabine and aspirin respectively were used for the imputation of treatment benefit in the model. Patients who experienced Grade 3 or 4 adverse events from aspirin or capecitabine were assumed to discontinue their use. In addition, the model assumed that no more than one AE could occur within each cycle. The risks of treatment-related side effects were assumed to cease immediately after completion of adjuvant treatment, and after treatment was prematurely terminated due to serious AEs. After five years, the risk of death from other causes was thought to be equal to that of the general population of the same age. Bleeding risk was estimated from cardiovascular aspirin studies and assumed to be equal in patients with resected CRC. Bleeding risk from aspirin was assumed to be uniform across the exposure period and beneficial effects of intervention were assumed to apply during the five-year aspirin regimen. Similarly, for capecitabine, the beneficial effects were assumed to apply for the first five years of the simulation. Unlike capecitabine which has a well-defined regimen for use in Stage II CRC, there is a dearth of literature especially on the optimal dose and duration of aspirin therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"

Good riskbenefit profile relative to chemotherapy, we hypothesize that Enzalutamide CYP17 inhibitor aspirin might represent a cost-effective strategy for the adjuvant treatment of Stage I and II CRC where the risk of cancer recurrence is low. Such patients are currently not routinely offered adjuvant chemotherapy and are followed-up with observation alone. As the number needed … Continue reading “We modeled aspirin to covering the critical period where recurrence easy to administer”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1643"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=1643"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1643\/revisions"}],"predecessor-version":[{"id":1644,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1643\/revisions\/1644"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=1643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=1643"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=1643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}